SciClone Pharma (SCLN) Tops Q1 EPS by 16c

SciClone Pharma (NASDAQ: SCLN) reported Q1 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $33.6 million versus the consensus estimate of $34 million.

As of March 31, 2015, cash, cash equivalents and short-term investments totaled $96.1 million, compared to $86.3 million as of December 31, 2014. SciClone has a share repurchase program under which its Board of Directors has authorized $80.5 million, of which approximately $68 million had been utilized through March 31, 2015.

For earnings history and earnings-related data on SciClone Pharma (SCLN) click here.

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• Leadership change and unchanged forecast send Avient stock tumbling 8%
• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance